COOCooper Companies

Health care · Eye Care · Nasdaq

The Cooper Companies, Inc. (Cooper, we or the Company), is a leading global medical device company focused on helping people experience life's beautiful moments. 10-K, Item 1

Headquarters: San Ramon, CA
Next results: around Dec 3, 2026

Compare with peers → Embed

The biggest changes in the 10-K filed 2025-12-05, this fiscal year against the last, and the sentences in the MD&A (Item 7) where management explains them, quoted word for word. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

18.1% → 16.7% (-1.4 pts) Big change FY to 2025-10-31 vs 2024-10-31

“CooperVision's operating income increased in fiscal 2025 compared to fiscal 2024, primarily due to the increase in net sales outpacing the increase in operating expenses.”
Read it in the 10-K ↗

“CooperSurgical's operating income decreased in fiscal 2025 compared to fiscal 2024, primarily due to inventory and long-lived asset write-offs, severance costs related to workforce optimization initiatives and an increase in amortization expense.”
Read it in the 10-K ↗

Cash from operations

+12.2% Big change FY to 2025-10-31 vs 2024-10-31

“Cash provided by operating activities in fiscal 2025 increased compared to fiscal 2024, primarily due to changes in prepaid and other assets and an increase in non-cash add-back of long-lived asset write-offs.”
Read it in the 10-K ↗

Gross margin

66.6% → 65.5% (-1.1 pts) Big change FY to 2025-10-31 vs 2024-10-31

“Consolidated gross margin decreased in fiscal 2025 to 66% compared to 67% in fiscal 2024, primarily driven by inventory and long-lived asset write-offs and severance costs related to workforce optimization initiatives.”
Read it in the 10-K ↗

Revenue

+5.1% FY to 2025-10-31 vs 2024-10-31

“CooperVision's growth in net sales in the Americas and EMEA was primarily attributable to market gains of silicone hydrogel contact lenses.”
Read it in the 10-K ↗

“In the fiscal year ended October 31, 2025, office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices and the acquisition of obp Surgical on August 1, 2024.”
Read it in the 10-K ↗

Net income

-4.4% FY to 2025-10-31 vs 2024-10-31

“The effective tax rate for fiscal 2025 and 2024 was higher than the U.S. federal statutory rate primarily due to foreign earnings subject to U.S. tax and foreign earnings in jurisdictions with different tax rates.”
Read it in the 10-K ↗

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K ↗

Work on COO in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/COO/export.csv") into a cell.